Fabry disease cardiac biomarker poster showing composite measurement concept across cardiac, fatigue, functional, and renal domains

Cardiac Biomarkers in Fabry Disease

By April 30, 2024August 17th, 2026Poster2 min read

Cardiac Biomarkers in Fabry Disease

Cardiac involvement is the leading cause of death in Fabry disease. However, no Fabry disease cardiac biomarker exists for monitoring it at home, and standard of care still addresses cardiac progression poorly. Patients feel that gap directly. In advisory sessions, they described not knowing when cardiac events occur, or how cardiac status shapes their daily fatigue.

This WORLDSymposium 2024 poster presents a composite measurement concept built to close it, developed by Koneksa with Amicus Therapeutics through a PRISMA literature search, nine patients living with Fabry disease, and eight treating clinicians.

View the poster and supplement, or contact us to discuss composite measurement design for your rare disease program.

Download the Poster

Complete the form to access the full resource.

What You'll Learn

What patients ranked as most important, and the wearable, ECG, and diary burden they said they would accept
How the composite concept maps devices and instruments to cardiac, fatigue, functional, and renal domains
What clinicians prioritized for staging cardiac progression, including LVH boundaries and the KCCQ
Why the work aligns to the Evidentiary Framework (V3) and FDA digital health technology guidance

Related Resources

koneksa_podcast_cover_image
Human-in-the-Loop: Why Experts Matter More in the Age of AIPodcast

Human-in-the-Loop: Why Experts Matter More in the Age of AI

Lodestar Webinar thumnbail
Meet Lodestar™: Your North Star for Regulatory SubmissionsWebinar

Meet Lodestar™: Your North Star for Regulatory Submissions

Cardiovascular measurement overview showing Koneksa's framework across cardiac physiology, mobility, imaging, biomarkers, and PROs
Cardiovascular MeasurementFact Sheet

Cardiovascular Measurement